KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.

Jeffrey Cummings, Sharon Cohen, Jennifer Murphy, Holly M Brothers, Mina Nejati, Fiona Forrestal, Carl de Moor, John O'Gorman, John Harrison, Judith Jaeger, Catherine Jane Mummery, Anton P Porsteinsson, Michele Potashman, Ying Tian, Lili Yang, Ping He, Samantha Budd Haeberlein

Alzheimers Dement 21(6) e70224

PMID40545559
PMCIDPMC12183105
DOI10.1002/alz.70224
发表日期2025-06-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

INTRODUCTION: In EMERGE (NCT02484547), participants receiving aducanumab had significantly less progression versus placebo on all prespecified clinical endpoints at week 78. Here, we explicate the clinical meaningfulness of these treatment effects by analyzing item-level data and the persistence of treatment benefit. METHODS: Participants with early Alzheimer's disease (AD) were stratified by apolipoprotein E (APOE) ε4 status and randomized (1:1:1) to receive low- or high-dose aducanumab, or placebo. Prespecified principal component analyses (PCAs) per the Statistical Analysis Plan were followed by post hoc examination of individual domains/items across all five clinical endpoints. Progression analysis assessed reduction in clinical decline. RESULTS: High-dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms. Delay of progression over 18 months was consistent across measures; treatment effects increased over time. DISCUSSION: Across multiple analyses aducanumab slowed cognitive decline, prolonged functional independence, and attenuated behavioral symptoms in participants with early AD. These outcomes comprise the elements of a clinically meaningful response to treatment. HIGHLIGHTS: Endpoints in EMERGE assessed different aspects of cognition, daily function, and behavioral symptoms. Treatment benefits were observed across subdomains on all five clinical endpoints. Aducanumab meaningfully slowed disease progression in participants with early AD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。